Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2026—Platelet transfusion in neonate and pediatric patients prevents or stops bleeding. Platelet donor characteristics, such as sex and age, and further processing and storage of platelet units may impact platelet increments, overall transfusion burden, and clinical outcomes in pediatric and neonate transfusion recipients. Platelet collection and processing steps vary across blood centers.
June 2026—Atypical endometriosis is a potential precursor of endometriosis-associated ovarian carcinoma. Despite this, identification of atypical endometriosis (AE) lacks established clinical implications and is not routinely incorporated in histopathological examinations for endometriosis. The authors conducted a study to determine the interobserver variability in AE diagnosis and classify features that may contribute to consistent identification and diagnosis.
June 2026—Studies of genetic variants in autism spectrum disorders have identified copy-number variants and single-nucleotide variants in more than 100 autism spectrum disorder-associated genes. However, much of the genetic and neurobiological bases of such disorders are still unclear. Some of the yet unexplained genetic basis of autism spectrum disorder (ASD) may lie in variants that may be difficult to detect by short-read whole genome sequencing (SR-WGS), such as specific structural variants and tandem repeats.
May 2026—Digital pathology has evolved substantially over the past decade. What started primarily as a platform for image storage now supports educational initiatives, remote signout, consultation, and image analysis deployment.
May 2026—Use of AI to define spatial patterns of tumor-infiltrating lymphocytes associated with patient outcome; Expanding the clinicopathologic spectrum of EWSR1::SSX-rearranged sarcomas
May 2026—Training in cell and gene therapy manufacturing via graduate medical education; Phase one trial of CRISPR-Cas9 gene editing targeting ANGPTL3
May 2026—Role of genetics and environment in shaping the human immune cell epigenome; Update on MRD in acute myeloid leukemia: a consensus document
April 2026—Circulating metabolites, genetics, and lifestyle factors in relation to future risk of type 2 diabetes; Clinical outcomes after COVID-19–positive donor heart transplantation in a pediatric population
April 2026—CAR T-cell therapy-related gastrointestinal toxicity: histologic features and morphologic mimics; Clinicopathologic and genomic characterization of granuloma-rich hepatocellular carcinoma
April 2026—Use of long-read sequencing to monitor diagnostic blind spots of inherited metabolic diseases; Diffuse large B-cell lymphoma: a biologically heterogenous disease
